The role of omega-3 polyunsaturated fatty acids supplementation in childhood: A review

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 1, 2013, Pages 42-55

  Ciccone, Marco M ^a   Scicchitano, Pietro ^a   Gesualdo, Michele ^a   Zito, Annapaola ^a   Carbonara, Santa ^a   Ricci, Gabriella ^a   Cortese, Francesca ^a   Giordano, Paola ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Cardiovascular risk; Childhood; Diet; Endothelial function; Omega 3; PUFAs

Indexed keywords

ARACHIDONIC ACID; CARBON; DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 120; HYDROGEN; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEUKOTRIENE B4; LINOLEIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTERIAL WALL THICKNESS; ARTICLE; ASTHMA; ATOPY; ATTENTION DEFICIT DISORDER; BEHAVIOR CHANGE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELL MIGRATION; CHEMICAL STRUCTURE; CHILDHOOD; CHILDHOOD OBESITY; CYTOKINE PRODUCTION; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; ECONOMIC DEVELOPMENT; ECZEMA; ENDOTHELIAL DYSFUNCTION; FAT INTAKE; FATTY ACID METABOLISM; FOLLOW UP; GROWTH; HUMAN; HYDROGEN BOND; INSULIN SENSITIVITY; LEARNING; MEDLINE; PHYSICAL ACTIVITY; PREGNANCY; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMATIC REVIEW (TOPIC); SYSTOLIC BLOOD PRESSURE; VISUAL ACUITY;

ADMINISTRATION, ORAL; AGE FACTORS; ANIMALS; CHILD; CHILD NUTRITIONAL PHYSIOLOGICAL PHENOMENA; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MEDICATION ADHERENCE; NUTRITIONAL STATUS; PATENTS AS TOPIC; TASTE;

EID: 84878762553     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574890111308010006     Document Type: Article

References (104)

1. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res 2012; 53: 2525-2545.
2. Kalupahana NS, Claycombe KJ, Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: Mechanistic insights. Adv Nutr 2011; 2: 304-316.
3. Patel PS, Forouhi NG, Kuijsten A, Schulze MB, van Woudenbergh GJ, Ardanaz E, et al. The prospective association between total and type of fish intake and type 2 diabetes in 8 European countries: EPIC-InterAct Study. Am J Clin Nutr 2012; 95:1445-1453.
4. Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. Mol Nutr Food Res 2012; 56:1073-1080.
5. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006; 83: 1505S-1519S.
6. Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, et al. Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis. 2011; 218: 110-116.
7. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010; 212: 252-259.
8. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
9. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: A meta-analysis of cohort studies. Circulation 2004; 109: 2705-2711.
10. [No authors listed]. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354: 447-455.
11. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2:757-761.
12. Mozaffarian D, Ascherio A, Hu FB, Stampfer MJ, Willett WC, Siscovick DS, et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111: 157-164.
13. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. J Clin Lipidol 2012; 6: 5-18.
14. Annuzzi G, Rivellese AA, Wang H, Patti L, Vaccaro O, Riccardi G, et al. Lipoprotein subfractions and dietary intake of n-3 fatty acid: The genetics of coronary artery disease in alaska natives study. Am J Clin Nutr 2012; 95: 1315-1322.
15. Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab 2007; 9: 70-80.
16. Micallef M, Munro I, Phang M, Garg M. Plasma n-3 Polyunsaturated Fatty Acids are negatively associated with obesity. Br J Nutr 2009; 102: 1370-1374.
17. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981; 2: 1190-1193.
18. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000; 71: 213S-223S.
19. Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. Br J Nutr 2012; 107: S195-S200.
20. Cicero AF, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Curr Vasc Pharmacol 2009; 7: 330-337.
21. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002; 346: 1113-1118.
22. Madsen T, Christensen JH, Thøgersen AM, Schmidt EB, Toft E. Intravenous infusion of n-3 polyunsaturated fatty acids and inducibility of ventricular tachycardia in patients with implantable cardioverter defibrillator. Europace 2010; 12: 941-946.
23. ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012; 367: 309-318.
24. Halim SA, Newby LK. Review: Omega-3 fatty acid supplements provide no protective benefit in cardiovascular disease. Ann Intern Med 2012; 157: JC2-JC3.
25. Ciccone MM, Miniello V, Marchioli R, Scicchitano P, Cortese F, Palumbo V, et al. Morphological and functional vascular changes induced by childhood obesity. Eur J Cardiovasc Prev Rehabil. 2011; 18: 831-835.
26. Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, antiinflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis 2008; 7: 37.
27. Lands WE. Biochemistry and physiology of n-3 fatty acids. FASEB J. 1992; 6: 2530-2536.
28. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1: 420-439.
29. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000; 71: 343S-348S.
30. Benatti P, Peluso G, Nicolai R, Calvani M. Polyunsaturated fatty acids: Biochemical, nutritional and epigenetic properties. J Am Coll Nutr 2004; 23: 281-302.
31. Capra V, Bäck M, Barbieri SS, Camera M, Tremoli E, Rovati GE. Eicosanoids and their drugs in cardiovascular diseases: Focus on atherosclerosis and stroke. Med Res Rev 2013; 33: 364-438.
32. Wang Y, Botolin D, Christian B, Busik J, Xu J, Jump DB. Tissuespecifi c, nutritional, and developmental regulation of rat fatty acid elongases. J Lipid Res 2005; 46: 706-715.
33. Depner CM, Torres-Gonzalez M, Tripathy S, Milne G, Jump DB. Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese ldlr-/- mice. J Nutr 2012; 142: 1495-1503.
34. Glaser C, Lattka E, Rzehak P, Steer C, Koletzko B. Genetic variation in polyunsaturated fatty acid metabolism and its potential relevance for human development and health. Matern Child Nutr 2011; 7: 27S-40S.
35. Tanaka T, Shen J, Abecasis GR, Kisialiou A, Ordovas JM, Guralnik JM, et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet 2009; 5: e1000338.
36. Imhoff-Kunsch B, Briggs V, Goldenberg T, Ramakrishnan U. Effect of n-3 long-chain polyunsaturated fatty acid intake during pregnancy on maternal, infant, and child health outcomes: a systematic review. Paediatr Perinat Epidemiol 2012; 26: S91-S107.
37. Nagakura T, Matsuda S, Shichijyo K, Sugimoto H, Hata K. Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000; 16: 861-865.
38. Mihrshahi S, Peat JK, Webb K, Oddy W, Marks GB, Mellis CM, et al. Effect of omega-3 fatty acid concentrations in plasma on symptoms of asthma at 18 months of age. Pediatr Allergy Immunol 2004; 15: 517-522.
39. Almqvist C, Garden F, Xuan W, Mihrshahi S, Leeder SR, Oddy W, et al. Omega-3 and omega-6 fatty acid exposure from early life does not affect atopy and asthma at age 5 years. J Allergy Clin Immunol 2007; 119: 1438-1444.
40. Frensham LJ, Bryan J, Parletta N. Influences of micronutrient and omega-3 fatty acid supplementation on cognition, learning, and behavior: methodological considerations and implications for children and adolescents in developed societies. Nutr Rev 2012; 70: 594-610.
41. Karr JE, Alexander JE, Winningham RG. Omega-3 polyunsaturated fatty acids and cognition throughout the lifespan: A review. Nutr Neurosci 2011; 14: 216-225.
42. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty acids in children with attention-deficit hyperactivity disorder. Am J Clin Nutr 2000; 71: 327S-330S.
43. Aben A, Danckaerts M. Omega-3 and omega-6 fatty acids in the treatment of children and adolescents with ADHD. Tijdschr Psychiatr 2010; 52: 89-97.
44. Itomura M, Hamazaki K, Sawazaki S, Kobayashi M, Terasawa K, Watanabe S, et al. The effect of fish oil on physical aggression in schoolchildren--a randomized, double-blind, placebo-controlled trial. J Nutr Biochem 2005; 16: 163-171.
45. Milte CM, Parletta N, Buckley JD, Coates AM, Young RM, Howe PR. Eicosapentaenoic and docosahexaenoic acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: A randomized controlled trial. Nutrition. 2012; 28: 670-677.
46. Voigt RG, Llorente AM, Jensen CL, Fraley JK, Berretta MC, Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attentiondeficit/ hyperactivity disorder. J Pediatr. 2001; 139: 189-196.
47. Kennedy DO, Jackson PA, Elliott JM, Scholey AB, Robertson BC, Greer J, et al. Cognitive and mood effects of 8 weeks' supplementation with 400 mg or 1000 mg of the omega-3 essential fatty acid docosahexaenoic acid (DHA) in healthy children aged 10-12 years. Nutr Neurosci 2009; 12: 48-56.
48. Huffman SL, Harika RK, Eilander A, Osendarp SJ. Essential fats: how do they affect growth and development of infants and young children in developing countries? A literature review. Matern Child Nutr 2011; 7: 44-65.
49. Dziechciarz P, Horvath A, Szajewska H. Effects of n-3 long-chain polyunsaturated fatty acid supplementation during pregnancy and/or lactation on neurodevelopment and visual function in children: A systematic review of randomized controlled trials. J Am Coll Nutr. 2010; 29: 443-454.
50. Ortega RM, Rodríguez-Rodríguez E, López-Sobaler AM. Effects of omega 3 fatty acids supplementation in behavior and nonneurodegenerative neuropsychiatric disorders. Br J Nutr 2012; 107: S261-S270.
51. Campoy C, Escolano-Margarit MV, Anjos T, Szajewska H, Uauy R. Omega 3 fatty acids on child growth, visual acuity and neurodevelopment. Br J Nutr 2012; 107: S85-S106.
52. Richardson AJ. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int Rev Psychiatry 2006; 18: 155-172.
53. Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: The Bogalusa Heart Study. J Pediatr 2007; 150: 12-17.
54. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307: 483-490.
55. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006; 1: 11-25.
56. Jackson-Leach R, Lobstein T. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes 2006; 1: 26-32.
57. Xue B, Yang Z, Wang X, Shi H. Omega-3 Polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 Pathway. PLoS One 2012; 7: e45990.
58. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012; 18: 363-374
59. Manco M, Calvani M, Mingrone G. Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab 2004; 6: 402-413.
60. Dangardt F, Chen Y, Gronowitz E, Dahlgren J, Friberg P, Strandvik B. High physiological omega-3 Fatty Acid supplementation affects muscle fatty acid composition and glucose and insulin homeostasis in obese adolescents. J Nutr Metab 2012; 2012: 395-757.
61. Scaglioni S, Verduci E, Salvioni M, Bruzzese MG, Radaelli G, Zetterström R, et al. Plasma long-chain fatty acids and the degree of obesity in Italian children. Acta Paediatr 2006; 95: 964-969.
62. Karlsson M, Mårild S, Brandberg J, Lönn L, Friberg P, Strandvik B. Serum phospholipid fatty acids, adipose tissue, and metabolic markers in obese adolescents. Obesity (Silver Spring) 2006; 14: 1931-1939.
63. Sinha R, Dufour S, Petersen KF, LeBon V, Enoksson S, Ma YZ, et al. Assessment of skeletal muscle triglyceride content by (1)H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 2002; 51: 1022-1027.
64. Manco M, Bottazzo G, DeVito R, Marcellini M, Mingrone G, Nobili V. Nonalcoholic fatty liver disease in children. J Am Coll Nutr 2008; 27: 667-676.
65. Clarke SD, Jump DB. Polyunsaturated fatty acid regulation of hepatic gene transcription. J Nutr 1996; 126: 1105S-1109S.
66. Groh-Wargo S, Jacobs J, Auestad N, O'Connor DL, Moore JJ, Lerner E. Body composition in preterm infants who are fed longchain polyunsaturated fatty acids: A prospective, randomized, controlled trial. Pediatr Res 2005; 57: 712-718.
67. Donahue SM, Rifas-Shiman SL, Gold DR, Jouni ZE, Gillman MW, Oken E. Prenatal fatty acid status and child adiposity at age 3 y: results from a US pregnancy cohort. Am J Clin Nutr 2011; 93: 780-788.
68. Rodríguez G, Iglesia I, Bel-Serrat S, Moreno LA. Effect of n-3 long chain polyunsaturated fatty acids during the perinatal period on later body composition. Br J Nutr 2012; 107: S117-S128.
69. Kaikkonen JE, Jula A, Mikkilä V, Viikari JS, Moilanen T, Nikkari T, et al. Childhood serum cholesterol ester fatty acids are associated with blood pressure 27 years later in the Cardiovascular Risk in Young Finns Study. Am J Clin Nutr 2012; 95: 1422-1431.
70. Skilton MR, Raitakari OT, Celermajer DS. High intake of dietary long-chain ω-3 fatty acids is associated with lower blood pressure in children born with low birth weight: NHANES 2003-2008. Hypertension 2013 Mar 4. [Epub ahead of print]
71. Mercuro G, Bassareo PP, Flore G, Fanos V, Dentamaro I, Scicchitano P, et al. Prematurity and low weight at birth as new conditions predisposing to an increased cardiovascular risk. Eur J Prev Cardiol 2012 Jan 19. [Epub ahead of print]
72. Forsyth JS, Willatts P, Agostoni C, Bissenden J, Casaer P, Boehm G. Long chain polyunsaturated fatty acid supplementation in infant formula and blood pressure in later childhood: Follow up of a randomised controlled trial. BMJ 2003; 326: 953.
73. van Rossem L, Wijga AH, de Jongste JC, Koppelman GH, Oldenwening M, Postma DS, et al. Blood pressure in 12-year-old children is associated with fatty acid composition of human milk: the prevention and incidence of asthma and mite allergy birth cohort. Hypertension 2012; 60: 1055-1060.
74. Armitage JA, Pearce AD, Sinclair AJ, Vingrys AJ, Weisinger RS, Weisinger HS. Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency. Lipids 2003; 38: 459-464.
75. Kennedy K, Ross S, Isaacs EB, Weaver LT, Singhal A, Lucas A, et al. The 10-year follow-up of a randomised trial of long-chain polyunsaturated fatty acid supplementation in preterm infants: effects on growth and blood pressure. Arch Dis Child 2010; 95: 588-595.
76. O'Sullivan TA, Bremner AP, Beilin LJ, Ambrosini GL, Mori TA, Huang RC, et al. Polyunsaturated fatty acid intake and blood pressure in adolescents. J Hum Hypertens 2012;26: 178-187.
77. Toth PP. Subclinical atherosclerosis: What it is, what it means and what we can do about it. Int J Clin Prac 2008; 62: 1246-1254.
78. Ciccone MM, Scicchitano P, Zito A, Gesualdo M, Sassara M, Calderoni G, et al. Different functional cardiac characteristics observed in term/preterm neonates by echocardiography and tissue doppler imaging. Early Hum Dev 2011; 87: 555-558.
79. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: A scientific statement from the American Heart Association. Hypertension 2009; 54: 919-950.
80. Lande MB, Carson NL, Roy J, Meagher CC. Effects of childhood primary hypertension on carotid intima media thickness: a matched controlled study. Hypertension 2006; 48: 40-44.
81. Järvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, Laine S, et al. Endothelial dysfunction and increased arterial intima- media thickness in children with type 1 diabetes. Circulation 2004; 109: 1750-1755.
82. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-370.
83. Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics 2006; 117: 1560-1567.
84. Woo KS, Chook P, Yu CW, Sung RY, Qiao M, Leung SS, et al. Overweight in children is associated with arterial endothelial dysfunction and intima-media thickening. Int J Obes Relat Metab Disord 2004; 28: 852-857.
85. Leeson CP, Mann A, Kattenhorn M, Deanfield JE, Lucas A, Muller DP. Relationship between circulating n-3 fatty acid concentrations and endothelial function in early adulthood. Eur Heart J 2002; 23: 216-222.
86. Skilton MR, Ayer JG, Harmer JA, Webb K, Leeder SR, Marks GB, et al. Impaired fetal growth and arterial wall thickening: a randomized trial of ω-3 supplementation. Pediatrics 2012; 129: e698-e703.
87. Hjerkinn EM, Abdelnoor M, Breivik L, Bergengen L, Ellingsen I, Seljeflot I, et al. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil 2006; 13: 325-333.
88. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-III32.
89. Widmer RJ, Freund MA, Flammer AJ, Sexton J, Lennon R, Romani A, et al. Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. Eur J Nutr 2012 Aug 8. [Epub ahead of print]
90. Heiss C, Jahn S, Taylor M, Real WM, Angeli FS, Wong ML, et al. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 2010; 56: 218-224.
91. Ros E, Núñez I, Pérez-Heras A, Serra M, Gilabert R, Casals E, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: A randomized crossover trial. Circulation. 2004; 109: 1609-1614.
92. Engler MM, Engler MB, Malloy M, Chiu E, Besio D, Paul S, et al. Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: Results from the EARLY study. Int J Clin Pharmacol Ther 2004; 42: 672-679.
93. Dangardt F, Osika W, Chen Y, Nilsson U, Gan LM, Gronowitz E, et al. Omega-3 fatty acid supplementation improves vascular function and reduces inflammation in obese adolescents. Atherosclerosis 2010; 212: 580-585.
94. Ayer JG, Harmer JA, Xuan W, Toelle B, Webb K, Almqvist C, et al. Dietary supplementation with n-3 polyunsaturated fatty acids in early childhood: Effects on blood pressure and arterial structure and function at age 8 y. Am J Clin Nutr 2009; 90: 438-446.
95. Weisinger HS, Armitage JA, Sinclair AJ, Vingrys AJ, Burns PL, Weisinger RS. Perinatal omega-3 fatty acid deficiency affects blood pressure in later life. Nat Med 2001; 7: 258-259.
96. Damsgaard CT, Schack-Nielsen L, Michaelsen KF, Fruekilde MB, Hels O, Lauritzen L. Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants. J Nutr 2006; 136: 94-99.
97. Myhre, J. Drinkable omega-3 preparation. WO2001047377A2 (2006).
98. Van-Anholt, R.D., Hofman, Z., Kiers, W.H.A. Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding. US20120309831A1 (2012).
99. Breivik, H. Omega-3 fatty acid fortified composition. US20100197785 (2010).
100. Mathisen, H., Mathisen, S.J. Drink comprising a combination of fish oil and probiotics. US20080286414 (2008).
101. Harris, W. Omega-3 fatty acid assays for disease risk assessment. WO2004087737A2 (2004).
102. Jackowski, G., MacSweeney, R., Shaikh, N., Yantha, J., Schini- Kerth, V. Method for treating obesity with anti-obesity formulations and omega-3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics. US20130034535A1 (2013).
103. Breivik, H., Borretzen, B., Dahl, K.H., Krokan, H.E., Bonaa, K.H. Treatment and prevention of risk factors for cardiovascular diseases. US005698594A (1997).
104. Jackowski, G., MacSweeney, R., Shaikh, N., Yantha, J., Schini-Kerth, V. Omega-3 formulations for treatment of risk factors for cardiovascular disease and protection against sudden death. US20120302639A1 (2012).